Home › Therapeutic areas › Neurology › Epilepsy
Epilepsy (8 companies)
Companies with an active program in Epilepsy.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics | Neurology Rare | 1 | Approved | $7.15B | 15 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.84B | 17 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 2 | Approved | $1.94B | 17 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $60.7M | 13 |
| OVID | Ovid Therapeutics | Neurology Rare | 1 | Phase 2 | $419M | 4 |
| RAPP | Rapport Therapeutics | Neurology | 2 | Phase 3 | $1.41B | 6 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 1 | Approved | $1.46B | 4 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 3 | NDA Submitted | $3.81B | 9 |
No companies match.